WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC codes 2019

ATC codeATC level name
A06AH05naldemedine
A07XA06crofelemer
A10BD23metformin and ertugliflozin
A10BD24sitagliptin and ertugliflozin
A10BD25metformin, saxagliptin and dapagliflozin
A10BH52gemigliptin and rosuvastatin
A10BK04ertugliflozin
A10BK05ipragliflozin
A16AX15telotristat
B01AX07caplacizumab
B02BX07lusutrombopag
B02BX08avatrombopag
B02BX09fostamatinib
B03XA05roxadustat
B06AC05lanadelumab
C01CX09angiotensin II
C02KX52ambrisentan and tadalafil
C09DX05valsartan and nebivolol
C09DX06candesartan, amlodipine and hydrochlorothiazide
D04AX01doxepin
D10AD06trifarotene
D11AH06crisaborole
D11AX25hydrogen peroxide
G01AX17dapivirine
G02BB02vaginal ring with progestogen
G03AA17medroxyprogesterone and estradiol
G03AB09norgestimate and ethinylestradiol
G03XXOther sex hormones and modulators of the genital system
G03XX01prasterone
G04CX04fexapotide
J01AA13eravacycline
J01DD18cefteram
J01DD64cefpodoxime and beta-lactamase inhibitor
J01DH06tebipenem pivoxil
J01DH52meropenem and vaborbactam
J01MA22tosufloxacin
J01MA23delafloxacin
J04AM07rifampicin, ethambutol and isoniazid
J04AM08isoniazid, sulfamethoxazole, trimethoprim and pyridoxine
J05AG06doravirine
J05AH03peramivir
J05AP57glecaprevir and pibrentasvir
J05AR23atazanavir and ritonavir
J05AR24lamivudine, tenofovir disoproxil and doravirine
J05AX17enisamium iodide
J05AX18letermovir
J05AX19tilorone
J05AX21pentanedioic acid imidazolyl ethanamide
J05AX23ibalizumab
L01AD08uramustine
L01BC09floxuridine
L01XC31avelumab
L01XC32atezolizumab
L01XE44lorlatinib
L01XE45neratinib
L01XE46encorafenib
L01XE47dacomitinib
L01XE48icotinib
L01XE50abemaciclib
L01XX58epacadostat
L01XX59enasidenib
L01XX60talazoparib
L01XX61copanlisib
L01XY01cytarabine and daunorubicin
L02AE51leuprorelin and bicalutamide
L02BB05apalutamide
L04AA38ozanimod
L04AA39emapalumab
L04AA40cladribine 1)
L04AC17tildrakizumab
M05BB09ibandronic acid and colecalciferol
N02CX08galcanezumab
N03AX24cannabidiol
N07XX12patisiran
N07XX13valbenazine
N07XX14edaravone
P01CA03fexinidazole
R03CC63clenbuterol and ambroxol
S01EX06omidenepag
S01XA26riboflavin
V04CX01indocyanine green
1) Oral formulations indicated for multiple sclerosis. Parenteral formulations are classified in L01BB04

Last updated: 2018-11-21